CompletedPhase 3

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease

Lead sponsor

TauRx Therapeutics Ltd

Asset

LMTM

Listed sites

Recruiting sites

Enrollment

800

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MMSE 20-26•Study partner/caregiver required•MRI contraindications excluded

Primary endpoints

•ADAS-Cog•ADCS-Activities of Daily Living (ADCS-ADL)•Number of study participants who tolerate oral doses of TRx0237

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01689233

Org study IDTRx-237-005

Timeline

Milestones

Study first posted2012-09-21estimated

Study start2012-10 (month precision)

Primary completion2016-05actual (month precision)

Study completion2016-05actual (month precision)

Last update posted2018-03-14actual

Assets

Drug assets

LMTM

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Maximum age89 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of all cause dementia and probable Alzheimer's disease

•Clinical Dementia Rating (CDR) total score of 0.5 or 1 (mild) and MMSE score of 20-26 (inclusive)

•Age <90 years

•Modified Hachinski ischemic score of ≤4

•Females, if of child-bearing potential, must practice true abstinence or be competent to use adequate contraception and agree to maintain this throughout the study

•Subject, and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with national law is/are able to read, understand, and provide written informed consent

•Has one (or more) identified adult caregiver who is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for ≥2 hours/day ≥3 days/week; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug

•If currently taking an acetylcholinesterase inhibitor and/or memantine at the time of Screening, the subject must have been taking such medication(s) for ≥3 months. The dosage regimen must have remained stable for ≥6 weeks and it must be planned to remain stable throughout participation in the study.

•Able to comply with the study procedures

Exclusion criteria

•Significant central nervous system (CNS) disorder other than Alzheimer's disease

•Significant focal or vascular intracranial pathology seen on brain MRI scan

•Clinical evidence or history of stroke, transient ischemic attack, significant head injury or other unexplained or recurrent loss of consciousness ≥15 minutes

•Epilepsy

•Major depressive disorder, schizophrenia, or other psychotic disorders, bipolar disorder, substance (including alcohol) related disorders

•Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MRI

•Resides in hospital or moderate to high dependency continuous care facility

•History of swallowing difficulties

•Pregnant or breastfeeding

•Glucose-6-phosphate dehydrogenase deficiency

•History of significant hematological abnormality or current acute or chronic clinically significant abnormality

•Abnormal serum chemistry laboratory value at Screening deemed to be clinically relevant by the investigator

•Clinically significant cardiovascular disease or abnormal assessments

•Preexisting or current signs or symptoms of respiratory failure

•Concurrent acute or chronic clinically significant immunologic, hepatic, or endocrine disease (not adequately treated) and/or other unstable or major disease other than Alzheimer's disease

•Diagnosis of cancer within the past 2 years prior to Baseline (other than basal cell or squamous cell skin cancer or Stage 1 prostate cancer) unless treatment has resulted in complete freedom from disease for at least 2 years

•Prior intolerance or hypersensitivity to methylthioninium-containing drug, similar organic dyes, or any of the excipients

•Treatment currently or within 3 months before Baseline with any of the following medications (unless otherwise noted):

-Tacrine

-Clozapine, olanzapine (and there is no intent to initiate therapy during the course of the study)

-Carbamazepine, primidone

-Drugs with a warning or precaution in the labeling of methemoglobinemia at approved doses

•Current or prior participation in a clinical trial as follows:

-Clinical trial of a product for cognition in which the last dose was received within 90 days prior to Screening (unless confirmed to have been randomized to placebo)

-A clinical trial of a drug, biologic, device, or medical food in which the last dose/administration was received within 28 days prior to Baseline

Endpoints (14)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Neuroimaging

Behavior / neuropsychiatric

Other (unclassified)

Global cognition

Function / daily living

Fluid / digital biomarkers

Caregiver / quality of life

Other clinical outcomes

Global cognition

1 endpoint

Secondary/protocol endpoint

Change from Baseline in Mini-Mental Status Examination (MMSE)

Time frame:78 weeks

Mini-Mental State Examination (MMSE)

change from baseline, improvement

Function / daily living

1 endpoint

Primary/protocol endpoint

Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)

Time frame:78 weeks

ADCS-Activities of Daily Living (ADCS-ADL)

change from baseline, improvement

Behavior / neuropsychiatric

2 endpoints

Secondary/protocol endpoint

Change from Baseline in Neuropsychiatric Inventory (NPI)

Time frame:78 weeks

Neuropsychiatric Inventory (NPI)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)

Time frame:78 weeks

change from baseline, improvement

Neuroimaging

5 endpoints

Primary/protocol endpoint

Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes

Time frame:78 weeks

event count, event

Secondary/protocol endpoint

Change in expected decline of whole brain volume as measured by brain MRI

Time frame:78 weeks

change from baseline, improvement

Other/protocol endpoint

Reduction in glucose uptake decline in the temporal lobe on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging

Time frame:78 weeks

change from baseline, improvement

Other/protocol endpoint

Change in expected increase in ventricular volume as measured by brain MRI

Time frame:78 weeks

change from baseline, improvement

Other/protocol endpoint

Change in expected decline in hippocampal volume as measured by brain MRI

Time frame:78 weeks

change from baseline, improvement

Fluid / digital biomarkers

1 endpoint

Other/protocol endpoint

Change in cerebrospinal fluid biomarkers of Alzheimer's Disease in subjects who separately consent to lumbar puncture

Time frame:78 weeks

change from baseline, improvement

Caregiver / quality of life

1 endpoint

Other/protocol endpoint

Change in resource utilization using the Resource Utilization in Dementia (RUD) Lite

Time frame:78 weeks

change from baseline, improvement

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Change from Baseline in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)

Time frame:78 weeks

change from baseline, improvement

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)

Time frame:78 weeks

ADAS-Cog

change from baseline, improvement

Other/protocol endpoint/low confidence

Compare the influence of Apolipoprotein E genotype on the primary and selected secondary outcomes in subjects by or for whom legally acceptable consent is separately provided

Time frame:78 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.